Last updated
CagriSema and tirzepatide are two different answers to the same question — how to beat semaglutide on weight. Tirzepatide engineers a second receptor (GIP) into one molecule; CagriSema instead co-formulates two peptides (amylin plus semaglutide). One is FDA-approved and one is investigational, and their trial numbers land close enough that the design philosophy is the real story.
Research reference only. Not medical advice, prescribing guidance, or a product recommendation.
| Dimension | CagriSema | Tirzepatide |
|---|---|---|
| What it is | Fixed combination of two peptides | One synthetic dual-agonist molecule |
| Mechanism | Amylin (cagrilintide) + GLP-1 (semaglutide) | GIP + GLP-1 co-agonism |
| Developer | Novo Nordisk | Eli Lilly |
| Dosing | Once weekly (injectable) | Once weekly (injectable) |
| Peak weight ↓ (trial) | ~20.4% (REDEFINE 1, 68 wk; up to 22.7% w/ full adherence) | ~22.5% (SURMOUNT-1, 72 wk, 15 mg) |
| Approval status | Investigational (Phase 3 REDEFINE) | FDA approved (Mounjaro 2022 · Zepbound 2023) |
| Molecular identity | No single formula — a co-formulation | 39-aa peptide, MW 4813.5 |
| Maturity of evidence | Phase 3 program reporting | Multiple completed Phase 3 + CV/OSA data |
Tirzepatide is a single 39-residue peptide designed to hit two incretin receptors at once — GIP and GLP-1 — and it is the approved benchmark, with ~22.5% mean weight loss in SURMOUNT-1 and a full Phase 3 record behind it. CagriSema takes the opposite route: instead of one multi-receptor molecule, Novo Nordisk combines two of its existing peptides in a single weekly injection — the amylin analog cagrilintide and the GLP-1 agonist semaglutide — pairing two different satiety systems.
In the Phase 3 REDEFINE 1 trial, CagriSema produced roughly 20.4% mean weight loss over 68 weeks (up to 22.7% under a full-adherence analysis) — clearly beating semaglutide alone (14.9%) and cagrilintide alone (11.5%), which is the proof that the amylin arm adds real effect. But it landed close to tirzepatide’s figure rather than above it, and below the ~25% the market had priced in. So the honest read is two comparably powerful approaches: an approved single molecule versus an investigational two-peptide combination.
−20.4% vs −14.9% (sema) vs −11.5% (cagri) vs −3.0% (placebo)
Mean body-weight change (obesity, no diabetes) · n=3417 · 68 wk — Treatment-policy estimand; up to −22.7% under full adherence
−22.5% vs −2.4% (placebo)
Mean body-weight change · n=2539 · 72 wk — Pivotal obesity trial for Zepbound
−13.7% vs −3.4% (placebo)
Mean body-weight change · n=1206 · 68 wk — Diabetes population — smaller loss, as expected for the class
These are two strong, comparably effective strategies rather than a clear winner. Tirzepatide is the FDA-approved single-molecule dual agonist with the deeper evidence base; CagriSema is the investigational two-peptide combination that clearly beats its own components but did not decisively exceed tirzepatide, and came in under lofty expectations. Note that REDEFINE and SURMOUNT are separate trials — this is a cross-trial comparison, not a head-to-head. These are population means, not predictions for any individual.
Tirzepatide is one synthetic molecule that activates two receptors (GIP and GLP-1). CagriSema is a fixed combination of two separate peptides — cagrilintide (an amylin analog) and semaglutide (a GLP-1 agonist). Both aim to exceed semaglutide’s weight loss, by different means: engineering one multi-receptor molecule versus combining two.
They are close. In REDEFINE 1, CagriSema reported ~20.4% mean weight loss over 68 weeks (up to 22.7% with full adherence); tirzepatide reported ~22.5% in SURMOUNT-1 over 72 weeks. These are different trials, not a head-to-head, so the numbers should not be read as a direct ranking.
No. CagriSema is investigational and in the Phase 3 REDEFINE program. Tirzepatide is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (weight management).
It clearly beat semaglutide and cagrilintide alone, confirming the combination works. The disappointment was relative to expectations — the market had anticipated ~25% weight loss, and ~20.4% fell short of that bar while still being a strong absolute result. This page is a research and educational reference.
Mechanism, evidence, and trade-offs between CagriSema and Tirzepatide — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.